Intervention not reported
Duloxetine low dose RCTs: 6 Participants: 1031 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
6 participants
Very low
Intervention not reported
Amitriptyline standard dose RCTs: 10 Participants: 997 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
10 participants
Very low
Intervention not reported
Esreboxetine standard dose RCTs: 1 Participants: 783 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
1 participants
Very low
Intervention not reported
Esreboxetine standard dose RCTs: 1 Participants: 828 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
Milnacipran standard dose RCTs: 2 Participants: 1298 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
2 participants
Low
Intervention not reported
Mirtazapine standard dose RCTs: 1 Participants: 422 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
Duloxetine low dose RCTs: 6 Participants: 1116 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
6 participants
Moderate
Intervention not reported
All‐cause mortality at day 28 · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention may leads to lower all‐cause mortality at day 28 (low certainty).
1 finding from 1 review
Intervention not reported
Discontinuation of study drug due to adverse events · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention probably leads to lower discontinuation of study drug due to adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at 14 days · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Admission to hospital or death · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention may leads to lower admission to hospital or death (low certainty).
1 finding from 1 review
Intervention not reported
Admission to ICU or death · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All initial symptoms resolved at 28 days, and up to the longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Time to symptom resolution · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life up to 28 days and longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
SAEs during the study period · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention may leads to lower SAEs during the study period (low certainty).
1 finding from 1 review
Intervention not reported
Any grade TEAE · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention showed no clear difference in any grade TEAE (moderate certainty).
1 finding from 1 review
Intervention not reported
Any grade TRAE · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention probably leads to higher any grade TRAE (moderate certainty).
1 finding from 1 review
Contribution to total daily fluoride intake · children
For children in high-fluoridated areas, the mean contribution was 41% (SD 24%).
1 finding from 1 review
Early childhood caries (ECC) · Healthy children under 6 years in South Africa
Parental tertiary education (vs high-school education) was associated with about 1.8 times higher odds of early childhood caries in South Africa (OR 1.77, 95% CI 1.22-2.57; 2 studies; not GRADE-rated).
1 finding from 1 review